公开(公告)号：US20230201186A1

公开(公告)日：2023-06-29

申请号：US18072490

申请日：2022-11-30

申请人： Bayer Aktiengesellschaft ,  Bayer Pharma Aktiengesellschaft ,  Deutsches Krebsforschungszentrum

发明人： Norbert SCHMEES ,  Lars WORTMANN ,  Dennis KIRCHOFF ,  Thi Thanh Uyen NGUYEN ,  Nicolas WERBECK ,  Ulf BÖMER ,  Kirstin PETERSEN ,  Christina KOBER ,  Detlef STÖCKIGT ,  Christian LECHNER ,  Robin Michael MEIER ,  Simon Anthony HERBERT ,  Isabel Patrizia KERSCHGENS ,  Dirk KOSEMUND ,  Rienk OFFRINGA ,  Mareike GREES

IPC分类号： A61K31/4545 ,  C07D401/14 ,  A61K31/498 ,  C07D413/14 ,  A61P37/04 ,  A61K31/55 ,  C07D401/04 ,  C07D405/14 ,  C07D417/14 ,  A61K31/496 ,  A61K31/4725 ,  A61P35/00 ,  A61K31/4709 ,  A61K45/06

CPC分类号： A61K31/4545 ,  C07D401/14 ,  A61K31/498 ,  C07D413/14 ,  A61P37/04 ,  A61K31/55 ,  C07D401/04 ,  C07D405/14 ,  C07D417/14 ,  A61K31/496 ,  A61K31/4725 ,  A61P35/00 ,  A61K31/4709 ,  A61K45/06

摘要： The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.

公开(公告)号：US20230113037A1

公开(公告)日：2023-04-13

申请号：US17634930

申请日：2020-08-10

申请人： Bayer Aktiengesellschaft ,  Bayer Pharma Aktiengesellschaft ,  DEUTSCHES KREBSFORSCHUNGSZENTRUM

发明人： Julien LEFRANC ,  Norbert SCHMEES ,  Ludwig ZORN ,  Robin Michael MEIER ,  Simon Anthony HERBERT ,  Judith GÜNTHER ,  Ilona GUTCHER ,  Lars RÖSE ,  Benjamin BADER ,  Detlef STÖCKIGT ,  Mátyás GORJÁNÁCZ ,  Christina KOBER ,  Bernd BUCHMANN ,  Stephan BÖHME ,  Ulrich BOTHE ,  Michael PLATTEN ,  Daniel BAUMANN

IPC分类号： C07D487/04

摘要： The present invention covers [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds of general formula (I) in which R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.

公开(公告)号：US20230032216A1

公开(公告)日：2023-02-02

申请号：US17783953

申请日：2020-12-10

申请人： DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS

发明人： Alexander Boehme ,  Saskia Trump ,  Luis Felipe Somarribas Patterson ,  Ahmed Sadik ,  Christiane A. Opitz

IPC分类号： C12Q1/6886

摘要： The present invention relates to the use of Interleukin-4-induced gene 1 (IL4I1) as well as metabolites as produced by IL4I1 as marker in diagnosis and therapy of cancer and related metastasis and/or resistance to immunotherapy.

公开(公告)号：US20220296681A1

公开(公告)日：2022-09-22

申请号：US17633351

申请日：2020-08-06

申请人： Deutsches Krebsforschungszentrum ,  Universität Heidelberg

发明人： Hellmut G. Augustin ,  Corinne Hübers ,  Ashik Ahmed Abdul Pari ,  Martin Petkov ,  Moritz Felcht

IPC分类号： A61K38/18 ,  G01N33/574

摘要： The present invention relates to an N-terminal fragment of an angiopoietin like 4 (ANGPTL4) polypeptide, or a therapeutically active variant thereof, for use in the treatment of cancer in a subject. Moreover, the present invention provides an agent which increases the amount of an N-terminal fragment of an angiopoietin like 4 (ANGPTL4) polypeptide for use in treating cancer. Further, encompassed by the present invention is a method for identifying a candidate compound for the treatment of cancer.

公开(公告)号：US20220281931A1

公开(公告)日：2022-09-08

申请号：US17750061

申请日：2022-05-20

申请人： Dana-Farber Cancer Institute, Inc. ,  Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts

发明人： Benjamin EBERT ,  Mikolaj SLABICKI ,  Eric S. FISCHER ,  Hojong YOON ,  Jonas KOEPPEL

IPC分类号： C07K14/47 ,  G01N33/68

摘要： The invention features methods for characterizing a cancer as sensitive or resistant to Bcl6 therapies, as well as compositions and methods for inducing the degradation or polymerization of a polypeptide of interest.

公开(公告)号：US20220249872A1

公开(公告)日：2022-08-11

申请号：US17597624

申请日：2020-07-16

申请人： Deutsches Krebsforschungszentrum

发明人： Joao Seco ,  Paulo Jorge Magalhaes Martins ,  Riccardo Dal Bello

IPC分类号： A61N5/10

摘要： A device (110) and a method for monitoring a treatment of a body part (112) of a patient (114) with a beam (116) comprising particles (118) are disclosed. Herein, the device (110) comprises—a beam delivering unit (120) designated for delivering a beam (116) comprising particles (118) and adjusting a direction (124) of propagation of the beam (116) onto a body part (112) of a patient (114); and—a verification unit (130) designated for verifying a range and a dose delivery of the particles (118) provided by the beam (116) to the body part (112) of the patient (114) by determining information about prompt-gamma radiation (140) generated by an interaction of the particles (118) with the body part (112) of the patient (114) at at least two individual interaction points (150), wherein the verification unit (130) comprises a symmetry axis (149) which is symmetrical with respect to the at least two individual interaction points (150) and which is located perpendicular with respect to the direction (124) of the propagation of the beam (116). The device (110) and the method may be used in the field of particle therapy, specifically for verifying a range and a dose delivery of the particles (118) provided by the beam (116) to the body part (112) of a patient (114), especially towards a tumorous tissue of the patient (114).

公开(公告)号：US20220195533A1

公开(公告)日：2022-06-23

申请号：US17599681

申请日：2020-03-28

申请人： DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS

发明人： Christiane A. OPITZ ,  Ahmed SADIK ,  Saskia TRUMP ,  Soumya R. MOHAPATRA ,  Sascha SCHÄUBLE ,  Erik FÄSSLER ,  Luis F. SOMARRIBAS PATTERSON

IPC分类号： C12Q1/6886 ,  G16B25/10 ,  G16B40/20 ,  G16B40/30

摘要： The present disclosure relates to the generation and uses of an improved set of biomarkers that are aryl hydrocarbon receptor (AHR) target genes, designated as “AHR biomarkers.” The AHR biomarkers described herein allow one to efficiently determine AHR activation groups and sub-groups, in particular for an improved classification of tumors. As used herein, AHR activation groups are called “AHR activation signatures”. The AHR biomarkers comprise markers that are important in diagnosis and therapy, for example for selecting patients for treatment with AHR activation modulating interventions, and monitoring of therapy response.

公开(公告)号：US20220194943A1

公开(公告)日：2022-06-23

申请号：US17692978

申请日：2022-03-11

申请人： THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Servi ,  Johann Wolfgang Goethe-Universität ,  Deutsches Krebsforschungszentrum

发明人： Giovanna Tosato ,  Michael J. DiPrima ,  Harald Schwalbe ,  Alix Tröster ,  Denis Kudlinzki ,  Nathalie Jores

IPC分类号： C07D473/34 ,  C07D401/14 ,  C07D403/14 ,  C07D413/14

摘要： Ephrin type receptor tyrosine kinase inhibitors, also known as Eph tyrosine kinase receptor inhibitors, for treating cancer, an inflammatory disease, an autoimmune disease, or a degenerative disease characterized at least in part by the abnormal activity or expression of the Eph receptor tyrosine kinase. The inhibitors are particularly useful for treating certain cancers.

公开(公告)号：US20220152149A1

公开(公告)日：2022-05-19

申请号：US17429532

申请日：2020-02-06

申请人： Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts

发明人： Peter KRAMMER ,  Heiko WEYD ,  Kevin BODE

IPC分类号： A61K38/17 ,  A61K47/54 ,  A61K9/16 ,  A61P37/06

摘要： The present invention relates to an annexin-coated particle, comprising a negatively charged phospholipid and an annexin non-covalently coupled thereto. The present invention further relates to a composition comprising an annexin-coated particle. Furthermore, the present invention relates to a product for use in a method of preventing or treating a disease selected from a chronic inflammatory disease, an autoimmune disease, an allergy, and a cancer, said product comprising an annexin-coated particle, and/or a composition. The present invention further relates to a method of preparing an annexin-coated particle.

公开(公告)号：US11320438B2

公开(公告)日：2022-05-03

申请号：US15772030

申请日：2016-10-31

申请人： ELECTROPHORETICS LIMITED ,  RUPRECHT-KARLS-UNIVERSITÄT ,  DKFZ DEUTSCHES KREBSFORSCHUNGSZENTRUM

发明人： Sasa Koncarevic ,  Karsten Kuhn ,  Peter Schulz-Knappe ,  Ian Hugo Pike ,  Christiane Opitz ,  Michael Platten

IPC分类号： G01N33/68 ,  G01N33/532

摘要： Tryptophan degradation is a key metabolic pathway controlling immune reactions and evidence suggests that during cancer progression generation of tryptophan metabolites may be fundamental for immune escape promoting the malignant phenotype of cancer cells in an autocrine fashion. The present invention relates to methods of measuring mass tag labelled tryptophan and metabolites thereof and methods using the labelled molecules for monitoring in a subject the effectiveness of a treatment and of disease recurrence after treatment, for stratifying patients and for diagnosing suppression of an immune response in a subject.